Cellceutix'  (CTIX) CEO Leo Ehrlich recently railed against Mako Research for negative articles written about his company.  TheStreet's Adam Feuerstein says the rant may have been a smokescreen to divert attention from the company's actual problems. Feuerstein believes the data the company reported concerning the Phase 2 study of its Prurisol drug were exaggerated and the company withheld important negative data from investors.

This article was written by a staff member of TheStreet.